Evidence map›Paper›PMID 36042056›Full record

Trial reportJournal of bone and mineral metabolism2022

Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer.

Kimito Yamada, Hiroshi Kaise, Tetsuya Taguchi, Jun Horiguchi, Shintaro Takao, Masato Suzuki, Tomoyuki Kubota, Daishu Miura, Kazutaka Narui, Kanae Tawaraya and 5 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of bone and mineral metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 1 country.

Kimito YamadaDepartment of Breast Oncology and Surgery, Tokyo Medical University Hospital, 6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan. toya0@tokyo-med.ac.jp.ORCID http://orcid.org/0000-0002-5443-7078
Hiroshi KaiseDepartment of Breast Oncology and Surgery, Tokyo Medical University Hospital, 6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
Tetsuya TaguchiDepartment of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Jun HoriguchiDepartment of Breast Surgery, International University of Health and Welfare, Chiba, Japan.
Shintaro TakaoDepartment of Breast Surgery, Hyogo Cancer Center, Hyogo, Japan.
Masato SuzukiDepartment of Surgery, National Hospital Organization Chiba Medical Center, Chiba, Japan.
Tomoyuki KubotaDepartment of Surgery, Kamiiida Daiichi General Hospital, Aichi, Japan.
Daishu MiuraAkasaka Miura Clinic, Tokyo, Japan.
Kazutaka NaruiDepartment of Breast and Endocrine Surgery, Yokohama City University Medical Center, Kanagawa, Japan.
Kanae TawarayaYokohama Sakae Kyosai Hospital, Yokohama, Japan.
Yurika MachidaDepartment of Medical Informatics, Niigata University Medical and Dental Hospital, Niigata, Japan.
Kouhei AkazawaDepartment of Medical Informatics, Niigata University Medical and Dental Hospital, Niigata, Japan.
Norio KohnoDepartment of Breast Surgery, Kobe Kaisei Hospital, Hyogo, Japan.
Takashi IshikawaDepartment of Breast Oncology and Surgery, Tokyo Medical University Hospital, 6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
JONIE Study Group
Tokyo Medical University · JPNiigata University Medical and Dental Hospital · JPHyogo Prefectural Cancer Center · JPInternational University of Health and Welfare · JPKamiichi General Hospital · JPKobe Kaisei Hospital · JPKyoto Prefectural University of Medicine · JPNational Hospital Organization · JPYokohama City University Medical Center · JPYokohama Sakae Kyosai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionβ-ray strontium-89 (Sr-89) intra-irradiation therapy has been approved and clinically used to reduce bone metastasis pain not alleviated by bone-modifying agents, external radiation, and analgesic agents. We examined the efficacy of zoledronic acid (ZOL) and Sr-89 combination therapy compared with ZOL alone in breast cancer patients with bone metastases. MATERIALS AND

methodsA randomized controlled trial was conducted on breast cancer patients with bone metastasis to compare the efficacy between ZOL monotherapy and ZOL plus Sr-89 combination therapy. The primary endpoints were changes in urinary NTX levels at 13 weeks and brief pain inventory scores. The secondary endpoints were analgesic drug usages, response rates, changes in bone metabolism markers, quality of life, and adverse event rates.

resultsThirty of the planned 60 cases were randomly assigned to ZOL alone or ZOL + Sr-89. There were no significant differences in the changes in urinary NTX levels between the 2 groups (P = 0.365). There was no consistent difference in the pain score changes between the 2 groups. Sr-89 addition to ZOL slightly reduced the white blood cell and platelet counts. However, all adverse events were Grade 1. Safety and analgesic drug dose reduction were more evident in ZOL + Sr-89.

conclusionThis trial showed the lack of benefits from Sr-89 addition to ZOL for breast cancer patients with painful bone metastases. However, safety and analgesic drug dose reduction were more evident in ZOL + Sr-89, indicating its potential for pain control. Sr-89 therapy is safe, thus more effective radiopharmaceuticals are anticipated.

Indexed as

Bone Density Conservation AgentsBone NeoplasmsBreast NeoplasmsDiphosphonatesFemaleHumansImidazolesPainQuality of LifeStrontium RadioisotopesZoledronic AcidBone Density Conservation AgentsDiphosphonatesImidazolesStrontium-89Strontium RadioisotopesZoledronic AcidBone metastasesBreast cancerBrief pain inventoryStrontium-89Zoledronic acid

Identifiers

PMID36042056
OpenAlexW4293691895

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.